Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Jan 8

PMID 39767802

Authors

Xinyi Zheng

Shengying Qin

Mingkang Zhong

Qinxia Xu

Cong Huai

Xiaoyan Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Tacrolimus is widely used as a first-line immunosuppressant in transplant immunology; however, its clinical application is constrained by the narrow therapeutic index and considerable interindividual variability. In this study, we identified the potential regulatory role of a novel promoter polymorphism, rs4519508 C > T, in the tacrolimus pharmacodynamic pathway.

Methods: Dual-luciferase reporter assays and bioinformatic analysis were applied to assess the impact of allelic variation. Electrophoretic mobility shift assays (EMSA) validated the altered binding of transcription factors. Quantitative real-time PCR (qRT-PCR), enzyme-linked immunosorbent assay (ELISA) and Western blots were used to determine the immunosuppressive effect of tacrolimus.

Results: Assays revealed that rs4519508 C > T markedly enhanced promoter activity. EMSA assays validated the binding of E2F6 to rs4519508 C (wild-type) and the binding was significantly weaker to the rs4519508 T (mutant-type). The overexpression of E2F6 significantly reduced the transcriptional activity and expression of PPP3R1 when the rs4519508 site presented as major C allele, an effect that was not observed with the rs4519508 T allele. Furthermore, the downregulation of E2F6 raises the level of downstream immune cytokines inhibited by TAC.

Conclusions: This study proposed that E2F6 suppresses the expression of PPP3R1, while rs4519508 C > T impairs the binding of E2F6, and thus elevates the level of PPP3R1, so that the inhibition of the downstream immune cytokines by TAC is attenuated. Our findings reported the potential regulatory role of a novel polymorphism, rs4519508 C > T, which may serve as pharmacodynamic-associated pharmacogenetic biomarker indicating individual response variability of tacrolimus, and thus aid the clinical management of transplant immunology.

References

Elens L, Sombogaard F, Hesselink D, van Schaik R, van Gelder T . Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013; 23(12):649-57. DOI: 10.1097/FPC.0000000000000001. View

Nishio H, Matsui K, Tsuji H, Tamura A, Suzuki K . Immunolocalization of calcineurin and FKBP12, the FK506-binding protein, in Hassall's corpuscles of human thymus and epidermis. Histochem Cell Biol. 2000; 114(1):9-14. DOI: 10.1007/s004180000168. View

Suzuki A, Guerrini M, Yamamoto K . Functional genomics of autoimmune diseases. Ann Rheum Dis. 2021; 80(6):689-697. DOI: 10.1136/annrheumdis-2019-216794. View

Cartwright P, Muller H, Wagener C, Holm K, Helin K . E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene. 1998; 17(5):611-23. DOI: 10.1038/sj.onc.1201975. View

Noceti O, Woillard J, Boumediene A, Esperon P, Taupin J, Gerona S . Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes. Clin Chem. 2014; 60(10):1336-45. DOI: 10.1373/clinchem.2014.223511. View

Yu S, Liao J, Tang M, Wang Y, Wei X, Mao L . A functional single nucleotide polymorphism in the tyrosinase gene promoter affects skin color and transcription activity in the black-boned chicken. Poult Sci. 2017; 96(11):4061-4067. DOI: 10.3382/ps/pex217. View

Kung L, Batiuk T, Palomo-Pinon S, Noujaim J, Helms L, Halloran P . Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant. 2002; 1(4):325-33. DOI: 10.1034/j.1600-6143.2001.10407.x. View

van Gelder T, van Schaik R, Hesselink D . Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014; 10(12):725-31. DOI: 10.1038/nrneph.2014.172. View

Liu J, Farmer Jr J, Lane W, Friedman J, Weissman I, Schreiber S . Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991; 66(4):807-15. DOI: 10.1016/0092-8674(91)90124-h. View

10.

Trimarchi J, Fairchild B, VERONA R, Moberg K, Andon N, Lees J . E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc Natl Acad Sci U S A. 1998; 95(6):2850-5. PMC: 19658. DOI: 10.1073/pnas.95.6.2850. View

11.

Rusnak F, Mertz P . Calcineurin: form and function. Physiol Rev. 2000; 80(4):1483-521. DOI: 10.1152/physrev.2000.80.4.1483. View

12.

Liu H, Leslie E, Carlson J, Beaty T, Marazita M, Lidral A . Identification of common non-coding variants at 1p22 that are functional for non-syndromic orofacial clefting. Nat Commun. 2017; 8:14759. PMC: 5355807. DOI: 10.1038/ncomms14759. View

13.

Shaw K, Ho A, Raghavan A, Kim J, Jain J, Park J . Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A. 1995; 92(24):11205-9. PMC: 40600. DOI: 10.1073/pnas.92.24.11205. View

14.

Durinck S, Spellman P, Birney E, Huber W . Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009; 4(8):1184-91. PMC: 3159387. DOI: 10.1038/nprot.2009.97. View

15.

Wu Z, Xu Q, Qiu X, Xu L, Jiao Z, Zhang M . FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients. Eur J Clin Pharmacol. 2018; 75(1):33-40. DOI: 10.1007/s00228-018-2546-x. View

16.

Seyhun Y, Ciftci H, Kekik C, Karadeniz M, Tefik T, Nane I . Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients. Int J Immunogenet. 2015; 42(3):147-60. DOI: 10.1111/iji.12192. View

17.

Shi X, Ma D, Li M, Zeng L, Chen J, Yang Y . Nuclear receptor TLX regulates islet beta cell proliferation via E2F6. Biochem Biophys Res Commun. 2019; 513(3):560-566. DOI: 10.1016/j.bbrc.2019.04.033. View

18.

Lin J, Musunuru K . From Genotype to Phenotype: A Primer on the Functional Follow-up of Genome-Wide Association Studies in Cardiovascular Disease. Circ Genom Precis Med. 2018; 11(2). PMC: 6003539. View

19.

Fioretto P, Najafian B, Sutherland D, Mauer M . Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients. Clin J Am Soc Nephrol. 2010; 6(1):101-6. PMC: 3022230. DOI: 10.2215/CJN.03850510. View

20.

Velasco G, Hube F, Rollin J, Neuillet D, Philippe C, Bouzinba-Segard H . Dnmt3b recruitment through E2F6 transcriptional repressor mediates germ-line gene silencing in murine somatic tissues. Proc Natl Acad Sci U S A. 2010; 107(20):9281-6. PMC: 2889045. DOI: 10.1073/pnas.1000473107. View